Insider Transactions in Q2 2025 at Bei Gene, Ltd. (BGNE)
Insider Transaction List (Q2 2025)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 24
2025
|
Xiaodong Wang Director |
SELL
Open market or private sale
|
Direct |
2,007
-65.73%
|
$531,855
$265.81 P/Share
|
|
Jun 23
2025
|
Lai Wang Global Head of R&D |
SELL
Open market or private sale
|
Direct |
1,028
-100.0%
|
$267,280
$260.0 P/Share
|
|
Jun 23
2025
|
John Oyler Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
3,174
-98.42%
|
$831,588
$262.24 P/Share
|
|
Jun 23
2025
|
Xiaobin Wu President and COO |
SELL
Open market or private sale
|
Direct |
1,363
-100.0%
|
$354,380
$260.0 P/Share
|
|
Jun 17
2025
|
Lai Wang Global Head of R&D |
SELL
Open market or private sale
|
Direct |
470
-100.0%
|
$117,970
$251.37 P/Share
|
|
Jun 17
2025
|
John Oyler Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
1,460
-100.0%
|
$373,760
$256.49 P/Share
|
|
Jun 17
2025
|
Xiaobin Wu President and COO |
SELL
Open market or private sale
|
Direct |
630
-100.0%
|
$157,500
$250.87 P/Share
|
|
Jun 16
2025
|
Lai Wang Global Head of R&D |
SELL
Open market or private sale
|
Direct |
1,177
-71.46%
|
$313,082
$266.4 P/Share
|
|
Jun 16
2025
|
Chan Henry Lee SVP, General Counsel |
SELL
Open market or private sale
|
Direct |
422
-100.0%
|
$112,252
$266.5 P/Share
|
|
Jun 16
2025
|
John Oyler Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
3,680
-71.6%
|
$978,880
$266.05 P/Share
|
|
Jun 16
2025
|
Xiaobin Wu President and COO |
SELL
Open market or private sale
|
Direct |
1,543
-40.05%
|
$408,895
$265.85 P/Share
|
|
Jun 11
2025
|
Titus B. Ball Principal Accounting Officer |
SELL
Open market or private sale
|
Direct |
134
-100.0%
|
$34,572
$258.36 P/Share
|
|
Jun 10
2025
|
Titus B. Ball Principal Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
29,601
+28.58%
|
-
|
|
Jun 10
2025
|
Aaron Rosenberg Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
63,674
+21.62%
|
-
|
|
Jun 10
2025
|
Chan Henry Lee SVP, General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
46,878
+14.17%
|
-
|
|
Jun 10
2025
|
Xiaobin Wu President and COO |
BUY
Grant, award, or other acquisition
|
Direct |
123,370
+8.83%
|
-
|
|
Jun 10
2025
|
Lai Wang Global Head of R&D |
BUY
Grant, award, or other acquisition
|
Direct |
86,359
+7.54%
|
-
|
|
Jun 10
2025
|
John Oyler Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
185,055
+2.19%
|
-
|
|
Jun 10
2025
|
Xiaodong Wang Director |
SELL
Open market or private sale
|
Direct |
41,760
-63.28%
|
$10,982,880
$263.1 P/Share
|
|
Jun 10
2025
|
Xiaodong Wang Director |
BUY
Exercise of conversion of derivative security
|
Direct |
41,760
+50.0%
|
$250,560
$6.5 P/Share
|
|
Jun 10
2025
|
Xiaodong Wang Director |
BUY
Grant, award, or other acquisition
|
Direct |
98,696
+1.87%
|
-
|
|
Jun 10
2025
|
Qingqing Yi Director |
SELL
Other acquisition or disposition
|
Direct |
29,614
-52.01%
|
-
|
|
Jun 06
2025
|
Xiaobin Wu President and COO |
SELL
Open market or private sale
|
Direct |
1,934
-51.01%
|
$489,302
$253.43 P/Share
|
|
Jun 06
2025
|
Lai Wang Global Head of R&D |
SELL
Open market or private sale
|
Direct |
1,402
-54.5%
|
$353,304
$252.77 P/Share
|
|
Jun 06
2025
|
Chan Henry Lee SVP, General Counsel |
SELL
Open market or private sale
|
Direct |
700
-83.57%
|
$179,200
$256.29 P/Share
|
|
Jun 06
2025
|
John Oyler Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
5,127
-55.54%
|
$1,297,131
$253.38 P/Share
|
|
May 21
2025
|
Qingqing Yi Director |
BUY
Grant, award, or other acquisition
|
Direct |
10,985
+16.17%
|
-
|
|
May 21
2025
|
Alessandro Riva Director |
BUY
Grant, award, or other acquisition
|
Direct |
10,985
+16.17%
|
-
|
|
May 21
2025
|
Olivier Brandicourt Director |
BUY
Grant, award, or other acquisition
|
Direct |
10,985
+28.67%
|
-
|
|
May 21
2025
|
Shalini Sharp Director |
BUY
Grant, award, or other acquisition
|
Direct |
10,985
+36.47%
|
-
|
|
May 21
2025
|
Anthony C Hooper Director |
BUY
Grant, award, or other acquisition
|
Direct |
10,985
+14.51%
|
-
|
|
May 21
2025
|
Corazon (Corsee) D. Sanders Director |
BUY
Grant, award, or other acquisition
|
Direct |
10,985
+16.1%
|
-
|
|
May 21
2025
|
Margaret Dugan Director |
BUY
Grant, award, or other acquisition
|
Direct |
10,985
+16.17%
|
-
|
|
May 21
2025
|
Baker Bros. Advisors LP |
BUY
Grant, award, or other acquisition
|
Indirect |
43,940
+12.92%
|
-
|
|
May 13
2025
|
Xiaodong Wang Director |
SELL
Open market or private sale
|
Direct |
41,760
-72.47%
|
$9,354,240
$224.06 P/Share
|
|
May 13
2025
|
Xiaodong Wang Director |
BUY
Exercise of conversion of derivative security
|
Direct |
41,760
+50.0%
|
$250,560
$6.5 P/Share
|
|
May 09
2025
|
John Oyler Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,990,603
-19.6%
|
$33,840,251
$17.85 P/Share
|
|
May 09
2025
|
John Oyler Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
4,055,415
+28.54%
|
$0
$0.5 P/Share
|
|
Apr 14
2025
|
Xiaodong Wang Director |
SELL
Open market or private sale
|
Direct |
41,760
-34.46%
|
$10,147,680
$243.52 P/Share
|
|
Apr 14
2025
|
Xiaodong Wang Director |
BUY
Exercise of conversion of derivative security
|
Direct |
41,760
+50.0%
|
$250,560
$6.5 P/Share
|
|
Apr 01
2025
|
Xiaobin Wu President and COO |
SELL
Open market or private sale
|
Direct |
51,921
-62.98%
|
$14,641,722
$282.13 P/Share
|
|
Apr 01
2025
|
Xiaobin Wu President and COO |
BUY
Exercise of conversion of derivative security
|
Direct |
51,921
+45.29%
|
$7,632,387
$147.19 P/Share
|